The most frequently reported treatment-emergent adverse events were gastrointestinal disorders (placebo vs. eclitasertib: 20% vs. 12.8%), condition aggravated/worsened COVID-19 pneumonia (placebo vs. eclitasertib: 20.0% vs. 8.5%), elevated alanine transaminase (placebo vs. eclitasertib: 10.0% vs. 12.8%), and infections (placebo vs. eclitasertib: 25% vs. 8.5%) (Supp Table 4). The gene discussed is GPT; the disease is digestive system disorder.